Positron emission tomography in ovarian cancer: 18F-deoxy-glucose and 16-18F-fluoro-17-estradiol PET

Journal of Ovarian Research

Volumn 2, Issue 1, 2009, Pages

  Yoshida, Yoshio ^a   Kurokawa, Tetsuji ^a   Tsujikawa, Tetuya ^a   Okazawa, Hidehiko ^a   Kotsuji, Fumikazu ^a  

^a UNIVERSITY OF FUKUI   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

16ALPHA FLUOROESTRADIOL F 18; ANDROGEN; ANTIESTROGEN; ANTINEOPLASTIC AGENT; AROMATASE INHIBITOR; CA 125 ANTIGEN; ESTROGEN RECEPTOR; FLUORODEOXYGLUCOSE F 18; FUROSEMIDE; GONADORELIN AGONIST; PROGESTERONE; RADIOPHARMACEUTICAL AGENT; UNCLASSIFIED DRUG;

CANCER CHEMOTHERAPY; CANCER DIAGNOSIS; CANCER SCREENING; CANCER STAGING; CANCER THERAPY; COMPUTER ASSISTED EMISSION TOMOGRAPHY; COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DRUG RECEPTOR BINDING; DRUG UPTAKE; HUMAN; NUCLEAR MAGNETIC RESONANCE IMAGING; OVARY CANCER; POSITRON EMISSION TOMOGRAPHY; PRIORITY JOURNAL; RECURRENT CANCER; REVIEW; SENSITIVITY AND SPECIFICITY; TRANSVAGINAL ECHOGRAPHY;

EID: 70450221982     PISSN: None     EISSN: 17572215     Source Type: Journal    
DOI: 10.1186/1757-2215-2-7     Document Type: Review

References (61)

1. Epithelial ovarian cancer. RF Ozols SC Rubin GM Thomas SJ Robboy, Principles and Practice of Gynecologic Oncology Philadelphia, Lippincott Williams & Wilkins, William JH, Carlos AP, Robert CY, 4 2004 841 918
2. Imaging in gynecologic malignancies. DG Bragg H Hricak, Cancer 1993 71 1648 51 8431900
3. Ovarian cancer: the clinical role of US, CT, and MRI. K Togashi, Eur Radiol. 2003 13 Suppl 4 87 L104 10.1007/s00330-003-1964-y 15018172
4. Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine. GJ Cook MN Maisey I Fogelman, Eur J Nucl Med 1999 26 1363 78 10.1007/s002590050597 10541839
5. Clinical role of FDG PET in evaluation of cancer patients. L Kostakoglu H Agress Jr SJ Goldsmith, Radiographics 2003 23 315 40 10.1148/rg.232025705 12640150
6. Positron emission tomography application for gynecologic tumors. Y Nakamoto T Saga S Fujii, Int J Gynecol Cancer 2005 15 701 9 10.1111/j.1525-1438. 2005.00245.x 16174216
7. Oncologic imaging in gynecologic malignancies. N Pandit-Taskar, J Nucl Med 2005 46 1842 50 16269598
8. Positron emission tomography in gynecological malignancies. R Kumar A Chauhan S Jana S Dadparvar, Expert Rev Anticancer Ther 2006 6 1033 44 10.1586/14737140.6.7.1033 16831075
9. Ovarian cancer. S Mironov O Akin N Pandit-Taskar LE Hann, Radiol Clin North Am 2007 45 149 66 10.1016/j.rcl.2006.10.012 17157627
10. A combined PET/CT scanner for clinical oncology. T Beyer DW Townsend T Brun PE Kinahan M Charron R Roddy J Jerin J Young L Byars R Nutt, J Nucl Med 2000 41 1369 79 10945530
11. Clinical performance of PET/CT in evaluation of cancer: additional value for diagnostic imaging and patient management. R Bar-Shalom N Yefremov L Guralnik D Gaitini A Frenkel A Kuten H Altman Z Keidar O Israel, J Nucl Med. 2003 44 8 1200 1209 12902408
12. Preoperative evaluation of pelvic masses with combined 18F-fluorodeoxyglucose positron emission tomography and computed tomography. Y Yamamoto H Oguri R Yamada N Maeda S Kohsaki T Fukaya, Int J Gynaecol Obstet 2008 102 124 7 10.1016/j.ijgo.2008.02.019 18423470
13. 18F-FDG PET/CT evaluation of patients with ovarian carcinoma. AH Iagaru ES Mittra IR McDougall A Quon SS Gambhir, Nucl Med Commun 2008 29 1046 51 10.1097/MNM.0b013e32831089cb 18987524
14. PET imaging in the management of tumors of testis and ovary: current thinking and future directions. S Basu D Rubello, Minerva Endocrinol 2008 33 229 56 18846028
15. FDG-PET in gynaecological cancers: recent observations. G Lucignani, Eur J Nucl Med Mol Imaging 2008 35 2133 9 10.1007/s00259-008-0929-4 18779962
16. In vivo imaging of estrogen receptor concentration in the endometrium and myometrium using FES PET - influence of menstrual cycle and endogenous estrogen level. T Tsuchida H Okazawa T Mori M Kobayashi Y Yoshida Y Fujibayashi H Itoh, Nucl Med Biol 2007 34 205 10 10.1016/j.nucmedbio.2006.12.003 17307128
17. Metabolic flare: indicator of hormone responsiveness in advanced breast cancer. JE Mortimer F Dehdashti BA Siegel A Trinkaus JA Katzenellenbogen MJ Welch, J Clin Oncol 2001 19 2797 2803 11387350
18. The positron emission tomography with F18 17beta-estradiol has the potential to benefit diagnosis and treatment of endometrial cancer. Y Yoshida T Kurokawa Y Sawamura A Shinagawa H Okazawa Y Fujibayashi F Kotsuji, Gynecol Oncol 2007 104 764 6 10.1016/j.ygyno.2006.10.024 17156828
19. Uterine tumors: pathophysiologic imaging with 16alpha-[18F]fluoro-17beta- estradiol and 18F fluorodeoxyglucose PET - initial experience. T Tsujikawa Y Yoshida T Mori T Kurokawa Y Fujibayashi F Kotsuji H Okazawa, Radiology 2008 248 599 605 10.1148/radiol.2482071379 18539894
20. Evaluation of 18F-FDG PET with bladder irrigation in patients with uterine and ovarian tumors. K Koyama T Okamura J Kawabe N Ozawa K Torii N Umesaki M Miyama H Ochi R Yamada, J Nucl Med 2003 44 353 8 12621000
21. Screening for cancer with PET and PET/CT: potential and limitations. H Schöder M Gönen, J Nucl Med 2007 48 4 18 10.2967/jnumed.107.044446 (Pubitemid 47397409)
22. Normal and abnormal 18F-FDG endometrial and ovarian uptake in pre- and postmenopausal patients: assessment by PET/CT. H Lerman U Metser D Grisaru A Fishman G Lievshitz E Even-Sapir, J Nucl Med 2004 45 266 71 14960646
23. Physiological 18F-FDG uptake in the ovaries and uterus of healthy female volunteers. S Nishizawa M Inubushi H Okada, Eur J Nucl Med Mol Imaging 2005 32 549 56 10.1007/s00259-004-1703-x 15599527
24. Incidental ovarian 18F-FDG accumulation on PET: correlation with the menstrual cycle. SK Kim KW Kang JW Roh JS Sim ES Lee SY Park, Eur J Nucl Med Mol Imaging 2005 32 757 63 10.1007/s00259-005-1771-6 15772859
25. Adnexal masses: comparison of specificity of endovaginal US and pelvic MR imaging. KA Jain DL Friedman TW Pettinger R Alagappan RB Jeffrey Jr FG Sommer, Radiology 1993 186 697 704 8430177
26. Characterization of adnexal masses: combination of color Doppler and conventional sonography compared with spectral Doppler analysis alone and conventional sonography alone. JN Buy MA Ghossain D Hugol K Hassen C Sciot JB Truc P Poitout D Vadrot, AJR Am J Roentgenol 1996 166 385 93 8553953
27. US characterization of ovarian masses: a meta-analysis. K Kinkel H Hricak Y Lu K Tsuda RA Filly, Radiology 2000 217 803 11 11110947
28. Imaging of the ovary and adnexa: clinical issues and applications of MR imaging. EK Outwater CJ Dunton, Radiology 1995 194 1 18 7997533
29. Adnexal masses: accuracy of characterization with transvaginal US and precontrast and postcontrast MR imaging. Y Yamashita M Torashima Y Hatanaka M Harada Y Higashida M Takahashi H Mizutani H Tashiro J Iwamasa K Miyazaki, Radiology 1995 194 557 65 7824738
30. Ovarian lesions: detection and characterization with gadolinium-enhanced MRI at 1.5 T. SK Stevens H Hricak JL Stern, Radiology 1991 181 481 8 1924792
31. Teratomas versus cystic hemorrhagic adnexal lesions: differentiation with proton-selective fat-saturation MR imaging. SK Stevens H Hricak Z Campos, Radiology 1993 186 481 8 8421755
32. Evaluation of positron emission tomography with tracer 18-fluorodeoxyglucose in addition to magnetic resonance imaging in the diagnosis of ovarian cancer in selected women after ultrasonography. K Kawahara Y Yoshida T Kurokawa Y Suzuki K Nagahara T Tsuchida H Okazawa Y Fujibayashi Y Yonekura F Kotsuji, J Comput Assist Tomogr 2004 28 505 16 10.1097/00004728-200407000-00011 15232382
33. Preoperative diagnosis of ovarian tumors with MR imaging: comparison with transvaginal sonography, positron emission tomography, and histologic findings. A Rieber K Nussle I Stohr D Grab S Fenchel R Kreienberg SN Reske HJ Brambs, AJR Am J Roentgenol 2001 177 123 9 11418411
34. Asymptomatic adnexal masses: correlation of FDG PET and histopathologic findings. S Fenchel D Grab K Nuessle J Kotzerke A Rieber R Kreienberg HJ Brambs SN Reske, Radiology 2002 223 780 8 10.1148/radiol.2233001850 12034950
35. FDG PET evaluation of mucinous neoplasms: correlation of FDG uptake with histopathologic features. KL Berger SA Nicholson F Dehdashti BA Siegel, AJR Am J Roentgenol 2000 174 1005 8 10749239
36. Ovarian and extraovarian endometriosis-associated cancer. S Modesitt G Tortolero-Luna J Robinson D Gershenson J Wolf, Obstet Gynecol 2002 100 788 10.1016/S0029-7844(02)02149-X 12383550
37. Diagnostic accuracy of 18F-FDG PET/CT in characterizing ovarian lesions and staging ovarian cancer: correlation with transvaginal ultrasonography, computed tomography, and histology. P Castellucci AM Perrone M Picchio T Ghi M Farsad C Nanni C Messa MC Meriggiola G Pelusi A Al-Nahhas D Rubello F Fazio S Fanti, Nucl Med Commun 2007 28 589 95 10.1097/MNM.0b013e3281afa256 17625380
38. Neoadjuvant chemotherapy followed by tumor debulking prolongs survival for patients with poor prognosis in International Federation of Gynecology and Obstetrics Stage IIIC ovarian carcinoma. W Kuhn S Rutke K Späthe B Schmalfeldt G Florack B von Hundelshausen D Pachyn K Ulm H Graeff, Cancer 2001 92 2585 2591 10.1002/1097-0142(20011115)92:10<2585::AID-CNCR16113.0.CO;2-# 11745193
39. Incremental benefits of FDG positron emission tomography over CT alone for the preoperative staging of ovarian cancer. Y Yoshida T Kurokawa K Kawahara T Tsuchida H Okazawa Y Fujibayashi Y Yonekura F Kotsuji, AJR Am J Roentgenol 2004 182 227 33 14684544
40. Diagnostic accuracy of integrated FDG-PET/contrast-enhanced CT in staging ovarian cancer: comparison with enhanced CT. K Kitajima K Murakami E Yamasaki Y Kaji I Fukasawa N Inaba K Sugimura, Eur J Nucl Med Mol Imaging 2008 35 1912 20 10.1007/s00259-008-0890-2 18682935
41. The role of 18F-fluoro-deoxyglucose positron emission tomography (18F-FDG PET) in diagnosis of ovarian cancer. W Schröder M Zimny C Rudlowski U Büll W Rath, Int J Gynecol Cancer 1999 9 117 122 10.1046/j.1525-1438.1999. 09903.x 11240752
42. The diagnostic value of PET/CT for primary ovarian cancer - a prospective study. S Risum C Høgdall A Loft AK Berthelsen E Høgdall L Nedergaard L Lundvall SA Engelholm, Gynecol Oncol 2007 105 145 9 10.1016/j.ygyno.2006.11.022 17229460
43. Prediction of suboptimal primary cytoreduction in primary ovarian cancer with combined positron emission tomography/computed tomography-a prospective study. S Risum C Høgdall A Loft AK Berthelsen E Høgdall L Nedergaard L Lundvall SA Engelholm, Gynecol Oncol 2008 108 265 70 10.1016/j.ygyno.2007.11.002 18055006
44. Whole-body PET with FDG is useful for following up an ovarian cancer patient with only rising CA-125 levels within the normal range. T Kurokawa Y Yoshida K Kawahara T Tsuchida Y Fujibayashi Y Yonekura F Kotsuji, Ann Nucl Med 2002 16 491 3 10.1007/BF02988649 12508842
45. FDG-PET for management of cervical and ovarian cancer. LJ Havrilesky SL Kulasingam DB Matchar ER Myers, Gynecol Oncol 2005 97 183 91 10.1016/j.ygyno.2004.12.007 15790456
46. Positron emission tomography/computed tomography imaging for the detection of recurrent ovarian and fallopian tube carcinoma: a retrospective review. S Makhija N Howden R Edwards J Kelley DW Townsend CC Meltzer, Gynecol Oncol 2002 85 53 8 10.1006/gyno.2002.6606 11925120
47. CA 125, PET alone, PET-CT, CT and MRI in diagnosing recurrent ovarian carcinoma A systematic review and meta-analysis. P Gu LL Pan SQ Wu L Sun G Huang, Eur J Radiol 2008 29 18162353
48. Performance of integrated FDG-PET/contrast-enhanced CT in the diagnosis of recurrent ovarian cancer: comparison with integrated FDG-PET/non-contrast- enhanced CT and enhanced CT. K Kitajima K Murakami E Yamasaki Y Domeki Y Kaji I Fukasawa N Inaba N Suganuma K Sugimura, Eur J Nucl Med Mol Imaging 2008 35 1439 48 10.1007/s00259-008-0776-3 18418592
49. Reproducibility of standardized uptake value measurements determined by 18F-FDG PET in malignant tumors. C Nahmias LM Wahl, J Nucl Med 2008 49 1804 8 10.2967/jnumed.108.054239 18927325
50. Expression of GLUT-1 glucose transfer, cellular proliferation activity and grade of tumor correlate with [F-18]-fluorodeoxyglucose uptake by positron emission tomography in epithelial tumors of the ovary. T Kurokawa Y Yoshida K Kawahara T Tsuchida H Okazawa Y Fujibayashi Y Yonekura F Kotsuji, Int J Cancer 2004 10;109 926 32 10.1002/ijc.20057 (Pubitemid 38500750)
51. Prognostic significance of histologic classification and grading of epithelial malignancies of the ovary. GD Malkasian Jr LJ Melton Jr PC O'Brien MH Greene, Am J Obstet Gynecol 1984 149 274 84 6328995
52. Long-term follow-up and prognostic factor analysis in advanced ovarian carcinoma: the Gynecologic Oncology Group experience. GA Omura MF Brady HD Homesley E Yordan FJ Major HJ Buchsbaum RC Park, J Clin Oncol 1991 9 1138 50 1904477
53. Toward the development of a universal grading system for ovarian epithelial carcinoma: testing of a proposed system in a series of 461 patients with uniform treatment and follow-up. Y Shimizu S Kamoi S Amada F Akiyama SG Silverberg, Cancer 1998 82 893 901 10.1002/(SICI)1097-0142(19980301)82:5<893: :AID-CNCR143.0.CO;2-W 9486579
54. Assessment of proliferative activity in ovarian neoplasms by flow and static cytometry. Correlation with prognostic features. PC Huettner DS Weinberg JM Lage, Am J Pathol 1992 141 699 706 1381562
55. Ki67 antigen immunostaining (MIB 1 monoclonal antibody) in serous ovarian tumors: index of proliferative activity with prognostic significance. GG Garzetti A Ciavattini G Goteri M De Nictolis D Stramazzotti G Lucarini G Biagini, Gynecol Oncol 1995 56 169 74 10.1006/gyno.1995.1026 7896180
56. The combined evaluation of p53 accumulation and of Ki-67 (MIB1) labelling index provides independent information on overall survival of ovarian carcinoma patients. G Viale P Maisonneuve E Bonoldi A Di Bacco P Bevilacqua GA Panizzoni U Radaelli G Gasparini, Ann Oncol 1997 8 469 76 10.1023/A:1008253429700 9233527
57. Immunohistochemical staining of GLUT1 in benign, borderline, and malignant ovarian epithelia. T Kalir BY Wang M Goldfischer RS Haber I Reder R Demopoulos CJ Cohen DE Burstein, Cancer 2002 94 1078 82 10.1002/cncr.10280 11920478
58. Expression of GLUT-1 glucose transporter in borderline and malignant epithelial tumors of the ovary. G Cantuaria A Magalhaes M Penalver R Angioli P Braunschweiger O Gomez-Marin R Kanhoush C Gomez-Fernandez M Nadji, Gynecol Oncol 2000 79 33 7 10.1006/gyno.2000.5910 11006027
59. Prediction of response to neoadjuvant chemotherapy by sequential F-18-fluorodeoxyglucose positron emission tomography in patients with advanced-stage ovarian cancer. N Avril S Sassen B Schmalfeldt J Naehrig S Rutke WA Weber M Werner H Graeff M Schwaiger W Kuhn, J Clin Oncol 2005 23 7445 53 10.1200/JCO.2005.06.965 16157939
60. Cost Analysis of FDG PET for Managing Patients with Ovarian Cancer. GT Smith KF Hubner T McDonald JA Thie, Clin Positron Imaging 1999 2 63 70 10.1016/S1095-0397(99)00013-8 14516542
61. [18F]FDG PET as a substitute for second-look laparotomy in patients with advanced ovarian carcinoma. S Kim JK Chung SB Kang MH Kim JM Jeong DS Lee MC Lee, Eur J Nucl Med Mol Imaging 2004 31 196 201 10.1007/s00259-003-1367-y 15129701